

February 14, 2024

To

The Secretary, Listing Department
BSE Limited (SME),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

Scrip No. 543363
BSE Symbol: PREVEST

Sub: Submission of Investor Presentation to be made to Analysts/Investors

Please find enclosed herewith the investor presentation to be made to Analysts/Investors on the Financial Results of Prevest Denpro Limited for the quarter ended December 31, 2023.

This presentation is being submitted in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The same is also made available on the Company's website www.prevestdenpro.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For Prevest Denpro Limited

AMAN

SADHOTRA

Digitally signed by
AMAN SADHOTRA
Date: 2024.02.14
17:19:41 +05'30'

Aman Sadhotra
Company Secretary and Compliance Officer
M. No- 66562

EARNING PRESENTATION

NINE MONTHS FY 24

DISCLAIMER

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Prevest Denpro Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost overruns on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

KEY HIGHLIGHT


	REVENUE (Rs. Lakhs)	PAT (Rs. Lakhs)	EBITDA (Rs. Lakhs)	PAT MARGIN (%)	EBITDA MARGIN (%)
NINE MONTHS FY 24	4221.68	1146	1597	27.15%	37.83%
NINE MONTHS FY 23	3778.02	1060	1569	28.06%	41.54%

*REVENUE DISTRIBUTION



* FY 24 - 3rd Quarter

STRATEGIC LEVERS OF GROWTH



BUSINESS HIGHLIGHT



Export to over
+90 countries
worldwide



+60
Dealers in India



+90
Overseas Agents

BOARD OF DIRECTORS

Atul Modi

(Chairman and MD)

Namrata Modi

Whole Time Director and CFO

Vaibhav Munjal

Additional Executive Director

Dr. Sai Kalyan Surapaneni

R&D Director

Niharika Modi

Non-Executive Director

Dr. Nikhil Shrikant Bobade

Independent Director

Dr. Sudeep Haralakatte Murthy

Independent Director

CA Pardeep Gandotra

Additional Independent Director

ADVISORY BOARD

Dr. Carolyn Primus

(BS, MS, PhD), USA

A renowned scientist,
inventor, educationist
and author

Prof. Francesco Inchingolo

(MD, DMD, O.M.F.S, M.P.H), Italy

Professor in Dentistry, University of Bari
"Aldo Moro", Italy

Prof. Dr. Alka Beotra

(MSc PhD)

Director Qatar Analytics and
BioResearch Laboratory

Dr. Vishal V. Pande

(M. Pharma, PhD)

Principal, N. N. Sattha College of
Pharmacy, Ahmednagar

Dr. KV Ramana Reddy

(MDS, FDSRCS (England),

FDSRCSI (Ireland)

Principal, Army College of Dental Science,
Hyderabad

Dr. Shishir Singh

(MDS, PhD)

Professor, Terna Dental
College, Navi Mumbai

COMPREHENSIVE PRODUCT PORTFOLIO

Product Categories	No. of products	Product Usage
Endodontics Materials	+25	Root canal treatment
Cements & Liners	+16	Luting and restorative applications
Composites	+8	Dental restoration and filling
Orthodontics Materials	+2	Used for Orthodontic applications
Finishing & Polishing	+5	Polishing & oral Prophylaxis
Auxiliaries	+6	Support in various dental procedures
Impression Materials	+6	Recording dental impressions
Tooth Whitening	+4	Whitening of discoloured teeth
Haemostatic Materials	+2	Controls haemostasis during dental procedures
Temporary Materials	+5	Temporary restoration and fillings
Lab Materials	+8	Used in the dental laboratory in the fabrication of artificial prosthesis
Adhesives, Bonding Agents & Etchants	+8	Bonding agents and etching materials used as adhesive in dentistry
Dental 3D Printing Resins	+7	Fabrication of Surgical Guides; dentine bases; Temporary and Permanent (Ceramic) Crowns; Bridges; Cast Models

OUR NEW SEGMENT

oradox™



ADVANCED ORAL CARE

Quality Accreditations

With a focus on product quality, the company has successfully implemented a very effective quality management system which has been approved by TUV SUD, Germany. With the strong quality management system, all production processes are subjected to stringent monitoring and intensive testing thus ensuring consistent quality and safety of our products. As a result of implementation of strong quality management system, Prevest DenPro has been certified with ISO 13485-2016, USFDA and EC Certificate. The company has also pass through the **Saudi FDA** regulatory compliances and has been successfully granted **SFDA**. The company has also received **MDSAP** certification which is a conformity to Medical Device Single Audit Program for USA, Canada & Brazil



STRATEGIC TECHNICAL RESEARCH AND TIE-UP

The Company has entered into collaboration with the following reputed dental universities & institutions for exchange of technical knowledge and conducting training & research on dental materials. The Company has also entered into technology transfer agreement with Sree Chitra Tirunal Institute for Medical Sciences & Technology, Kerala for know-how for the manufacture of bioactive bone grafting materials.



Strengths and Opportunities



Well - established global sales network

With consistent marketing efforts over the years, the Company has been able to make its product reach to over 90 countries with network of 53 national dealers and 91 overseas agents



B2B and B2C Sales Model

Along with B2B Sales (i.e. sales to dealers and agents), the Company is connecting directly with consumers through its own online portal (prevestdirect.com), GEM Portal and other online marketplaces



Comprehensive Product Portfolio

In the last two decades of operations, the Company has been successful in establishing a comprehensive portfolio of over 100 dental products covering endodontics, orthodontics, composites, impression materials, finishing & polishing materials, auxiliaries' materials, hemostatic materials, temporary materials, lab materials, adhesives, cement & liners and tooth whitening.



Research Collaboration with prominent academic institutes

The Company has entered into collaboration with 12 reputed dental universities & institutions of India for exchange of technical knowledge and conducting training & research on dental materials.



Strong Advisory Board & Management

The promoters of the company have a combined experience of over 40 years in dental industry backed up with strong management team. It also has an advisory board of experienced & highly educated dental professionals.

The background is a dark, blurred image featuring financial data visualizations. On the left, a line graph with white circular markers connects several points. In the center, there are faint, overlapping bar charts. On the right, another line graph is visible, with a prominent peak. Numerical values are scattered throughout the background, including '245.57' at the top right, '183.102' in the middle left, and '154.178' near the bottom center. The overall aesthetic is professional and data-oriented.

FINANCE

The background of the slide features a dark, blurred image of a financial chart. It includes a line graph with white circular markers and numerical values such as '245.57' and '154.178'. There are also faint bar chart elements visible. The overall aesthetic is professional and data-oriented.

Profit and Loss (Standalone)

PARTICULARS		Quarter Ended			Nine Month Ended		Rs in Lakh
		12/31/2023 Unaudited	9/30/2023 Unaudited	12/31/2022 Unaudited	12/31/2023 Unaudited	12/31/2022 Unaudited	3/31/2023 Audited
1	Income From Operation						
	(a) Net Sales / Income from Operation (Net of Taxes)	1,362.32	1,317.78	1,226.73	4,019.50	3,608.06	4,985.41
	(b)Other Income	67.94	73.72	50.13	202.18	170.02	203.35
	Total Revenue	1,430.27	1,391.50	1,276.86	4,221.68	3,778.08	5,188.76
2	Expenses						
	(a) Cost of Material Consumed	306.21	351.01	300.52	1,010.05	976.81	1,276.08
	(b) Purchase of Stock-in- Trade	-	-	-			-
	(c)Changes in inventories of finished goods, work-in-progress and stock-in- trade	-3.11	(5.09)	(8.85)	(17.41)	(17.89)	(15.29)
	(d) Finance Cost	-	-	-		-	-
	(d) Employee benefit expenses	239.56	230.71	205.95	709.88	589.61	819.07
	(e) Depreciation and amortization expenses	42.06	21.95	18.31	81.50	51.83	67.51
	(f) Other Expenses	372.21	290.49	232.65	922.27	660.19	945.71
	Total Expenses	956.93	889.07	748.58	2,706.29	2,260.55	3,093.09
3	Profit/(Loss) from before exceptional and extraordanry items (1-2)	473.34	502.43	528.28	1,515.39	1,517.53	2,095.68
	Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)	473.34	502.43	528.28	1,515.39	1,517.53	2,095.68
	Financial Cost						
	Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)	473.34	502.43	528.28	1,515.39	1,517.53	2,095.68
4	Exceptional Item						
5	Profit/(Loss) from ordinary activities before tax (3+4)	473.34	502.43	528.28	1,515.39	1,517.53	2,095.68
6	Tax Expenses						
	Current Tax	105.27	113.84	163.71	354.49	449.58	516.16
	Earliyer Year Tax	-	-	1.73	-	0.27	0.27
	Deffered Tax	4.56	14.55	3.99	14.88	7.44	8.24
7	Net Profit/(Loss) from Ordinary activity after tax (5-6)	363.51	374.04	358.84	1,146.01	1,060.24	1,571.01
8	Extraordinary Item (net of tax Rs expenses)						
9	Net profit/(loss) for the period (7+8)	363.51	374.04	358.84	1,146.01	1,060.24	1,571.01
	Details of Share Capital						
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00	120.00	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accounting year.						6,079.44
11	Earnings per Share (EPS) , in Rs (not annualised)						
	(Equity Share of face value of Rs 10/- each)						
	(a) Basic	3.03	3.12	2.99	9.55	8.84	13.09
	(b) Diluted	3.03	3.12	2.99	9.55	8.84	13.09

The background of the slide features a blurred financial chart with a line graph and several data points. The chart is rendered in a light gray color against a dark background. The text "Profit and Loss (Consolidated)" is centered on a white rectangular background.

Profit and Loss (Consolidated)

PARTICULARS		Quarter Ended		Nine Month Ended
		12/31/2023	9/30/2023	12/31/2023
		Unaudited	Unaudited	Unaudited
1	Income From Operation			
	(a) Net Sales / Income from Operation (Net of Taxes)	1,362.45	1317.54	4,019.38
	(b)Other Income	67.94	73.72	202.18
	Total Revenue	1,430.39	1,391.26	4,221.56
2	Expenses			
	(a) Cost of Material Consumed	306.21	351.01	1,010.05
	(b) Purchase of Stock-in- Trade	-	-	-
	(c)Changes in inventories of finished goods, work-in-progress and stock-in- trade	(3.06)	(5.33)	(17.60)
	(d) Finance Cost	-	-	-
	(d) Employee benefit expenses	252.38	238.72	730.70
	(e) Depreciation and amortization expenses	42.06	21.95	81.50
	(f) Other Expenses	359.37	292.24	911.18
	Total Expenses	956.96	898.59	2,715.83
3	Profit/(Loss) from before exceptional and extraordanry items (1-2)	473.43	492.67	1,505.73
4	Exceptional Item			
5	Profit/(Loss) from ordinary activities before tax (3+4)	473.43	492.67	1,505.73
6	Tax Expenses			
	Current Tax	105.26	113.84	354.49
	Deffered Tax	4.55	14.55	14.88
7	Net Profit/(Loss) from Ordinary activity after tax (5-6)	363.61	364.28	1,136.35
8	Extraordinary Item (net of tax Rs expenses)			
9	Net profit/(loss) for the period (7+8)	363.61	364.28	1,136.35
10	Details of Share Capital			
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accounting year.			
11	Earnings per Share (EPS) , in Rs (not annualised)			
	(Equity Share of face value of Rs 10/- each)			
	(a) Basic	3.03	3.04	9.47
	(b) Diluted	3.03	3.04	9.47



THANK YOU